Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NRBONASDAQ:PHIONASDAQ:PLXPNASDAQ:PTPI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNRBONeuroBo Pharmaceuticals$0.68-3.4%$0.75$2.08▼$5.30$5.83M-0.2651,808 shs51,705 shsPHIOPhio Pharmaceuticals$2.18-4.0%$2.15$0.97▼$9.79$10.87M0.842.44 million shs120,268 shsPLXPPLx Pharma$0.00$0.02▼$0.04$603K3.7912.96 million shs3,000 shsPTPIPetros Pharmaceuticals$0.03+6.4%$0.31$0.02▼$16.25$938K1.573.14 million shs997,598 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNRBONeuroBo Pharmaceuticals0.00%-7.65%-14.40%-57.21%-83.35%PHIOPhio Pharmaceuticals-3.96%-12.10%+24.57%+67.05%-64.64%PLXPPLx Pharma0.00%0.00%0.00%0.00%0.00%PTPIPetros Pharmaceuticals+5.99%+11.48%-22.82%-97.92%-99.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals3.1011 of 5 stars3.55.00.00.01.12.50.6PLXPPLx PharmaN/AN/AN/AN/AN/AN/AN/AN/APTPIPetros Pharmaceuticals0.2385 of 5 stars0.03.00.00.00.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNRBONeuroBo Pharmaceuticals 0.00N/AN/AN/APHIOPhio Pharmaceuticals 3.00Buy$14.00542.20% UpsidePLXPPLx Pharma 0.00N/AN/AN/APTPIPetros Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NRBO, PLXP, PTPI, and PHIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.004/8/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$1.50 per shareN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$0.69 per shareN/APLXPPLx Pharma$4.54M0.00N/AN/A$1.30 per share0.00PTPIPetros Pharmaceuticals$5.11M0.18N/AN/A$4.04 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNRBONeuroBo Pharmaceuticals-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%8/12/2025 (Estimated)PHIOPhio Pharmaceuticals-$7.15M-$10.92N/A0.58N/AN/A-105.65%-89.19%8/13/2025 (Estimated)PLXPPLx Pharma-$46.13M-$1.85N/AN/AN/A-606.91%-291.11%-119.43%N/APTPIPetros Pharmaceuticals-$8.16M-$119.00N/A∞N/AN/A-78.22%-23.50%N/ALatest NRBO, PLXP, PTPI, and PHIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PTPIPetros PharmaceuticalsN/A-$8.46N/A-$9.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNRBONeuroBo PharmaceuticalsN/A2.412.41PHIOPhio PharmaceuticalsN/A10.5810.58PLXPPLx PharmaN/A4.794.28PTPIPetros Pharmaceuticals1.580.850.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNRBONeuroBo Pharmaceuticals1.37%PHIOPhio Pharmaceuticals57.31%PLXPPLx Pharma21.19%PTPIPetros Pharmaceuticals12.34%Insider OwnershipCompanyInsider OwnershipNRBONeuroBo Pharmaceuticals1.05%PHIOPhio Pharmaceuticals0.59%PLXPPLx Pharma8.95%PTPIPetros Pharmaceuticals12.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNRBONeuroBo Pharmaceuticals108.62 million8.53 millionNot OptionablePHIOPhio Pharmaceuticals104.80 million4.77 millionNot OptionablePLXPPLx Pharma1629.14 million26.53 millionNot OptionablePTPIPetros Pharmaceuticals2031.16 million9.93 millionNot OptionableNRBO, PLXP, PTPI, and PHIO HeadlinesRecent News About These CompaniesPetros Pharmaceuticals to appeal Nasdaq delisting decisionMay 23, 2025 | uk.investing.comPetros Pharmaceuticals Announces Transition from NASDAQ to OTC MarketsMay 21, 2025 | accessnewswire.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device DeveloperMay 20, 2025 | finanznachrichten.dePetros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device DeveloperMay 20, 2025 | accessnewswire.comPetros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI PlatformMay 6, 2025 | accessnewswire.comPetros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification ReformsApril 29, 2025 | accessnewswire.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple IndicationsMarch 20, 2025 | finanznachrichten.dePetros Pharmaceuticals enters collaboration with big data, analytics firmMarch 20, 2025 | msn.comPetros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple IndicationsMarch 20, 2025 | accessnewswire.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal StudyFebruary 27, 2025 | finanznachrichten.dePetros Pharmaceuticals announces top-line results of expanded App Comp studyFebruary 25, 2025 | markets.businessinsider.comPetros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal StudyFebruary 25, 2025 | accessnewswire.comPetros Pharmaceuticals prices 40M shares at 24c in public offeringFebruary 18, 2025 | markets.businessinsider.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and WarrantsFebruary 18, 2025 | finanznachrichten.dePetros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and WarrantsFebruary 18, 2025 | accessnewswire.comPetros Pharmaceuticals files to sell units, no amount givenJanuary 25, 2025 | markets.businessinsider.comPetros Pharmaceuticals modifies terms with investorsJanuary 24, 2025 | msn.comPetros Pharmaceuticals Inc (PTPI) Stock’s 0.02% Increase This Year: What’s the Story?January 8, 2025 | bovnews.comPetros announces ‘conducive position’ with newly approved FDA OTC final rulesJanuary 7, 2025 | markets.businessinsider.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final RulesJanuary 7, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRBO, PLXP, PTPI, and PHIO Company DescriptionsNeuroBo Pharmaceuticals NASDAQ:NRBO$0.68 -0.02 (-3.41%) As of 06/20/2025NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.Phio Pharmaceuticals NASDAQ:PHIO$2.18 -0.09 (-3.96%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$2.22 +0.04 (+2.06%) As of 06/23/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.PLx Pharma NASDAQ:PLXPPLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.Petros Pharmaceuticals NASDAQ:PTPI$0.03 +0.00 (+6.36%) As of 06/23/2025 03:48 PM EasternPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
